Download Complimentary Report Summary

Protect brand revenues with a multi-tiered counter-generics strategy:

Generic drugs now account for more than 60% of all prescriptions filled in the US, and more than $60 billion worth of drugs face US patent expiration by 2011.

Use this report to build a counter-generics strategy that includes long-term, R&D-based lifecycle planning (such as new formulations and next-generation drugs) as well as frontline tactics (such as litigation and counter-promotion) - and understand how companies launch authorized generics and attempt OTC switches.

Explore primary data for a comprehensive look at current counter-generics defense:

• Investigate strategies, investments and results for seven brands
• Benchmark your efforts against timelines, investment levels, and past-and-future use of critical lifecycle management and counter-generics options:

• Compare headcounts dedicated to counter-generics preparation over the life of a brand

Call Adam Bianchi  at 919-433-0202 to get your own copy of "Combating Generics" today.